Results 241 to 250 of about 42,096 (271)

Acquired angioedema

Journal of the American Academy of Dermatology, 1997
Acquired angioedema (AAE) is a rare disorder that has been categorized into two forms, AAE-I and AAE-II. AAE-I is associated with other diseases, most commonly B-cell lymphoproliferative disorders. AAE-II is defined by the presence of an autoantibody directed against the C1-inhibitor molecule.
openaire   +2 more sources

Angioedema

Clinical Pediatrics, 2007
Sanjay, Chawla, Mark, Riederer
openaire   +2 more sources

Angioedema

Allergy and Asthma Proceedings, 1990
S, Wong, I, Lawrence
openaire   +2 more sources

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2023
Isao Ohsawa, William R Lumry, Emel Aygören-Pürsün   +2 more
exaly  

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

Lancet, The, 2022
Timothy Craig, Markus Magerl, Donald S Levy   +2 more
exaly  

Hereditary Angioedema

International Journal of Dermatology, 1983
C M, Brickman, S W, Hosea
openaire   +2 more sources

An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial

Lancet, The, 2023
Emel Aygören-Pürsün, Andrea Zanichelli, Mauro Cancian   +2 more
exaly  

Hereditary Angioedema

New England Journal of Medicine, 1996
M. Cicardi, A. Agostoni
openaire   +1 more source

Prophylaxis with anti-activated factor XII for hereditary angioedema

Lancet, The, 2022
Lauré M Fijen, Marcel Levi
exaly  

Inhibition of Prekallikrein for Hereditary Angioedema

New England Journal of Medicine, 2022
Brenda F Baker, Marc A Riedl, William R Lumry   +2 more
exaly